Michael Tal
Professor, Radiology @ Yale University
Michael Tal is a Series A investor at Yale University focused on Health Care and Manufacturing. Prof. Tal is a associate Professor of Radiology at the Yale University School of Medicine since 1999.Mr. Tal is an interventional radiologist with expertise in minimally invasive procedures.Michael Graduated from Hadassah Medical School in Jerusalem , Israel in 1995, and completed medical training at MCP Hahnemann University inPhiladelphia and Yale University in 2000.He Completed his MBA at Yale business school in 2007.Prof. Tal is a Co-founded several medical device companies and brought several medical devices to market in the US . Prof. Tal is partner in Access Medical Ventures, a US-based venture capital fund that focuses specifically on investing and advancing medical device start-ups. He has cofounded several medical device companies and brought several medical devices to market in the US.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Michael Tal invests in
Stages Michael Tal invests in
Countries Michael Tal invests in
Investment Focus
Industry
- Health Care 1 (25%)
- Manufacturing 1 (25%)
- Medical Device 1 (25%)
Stage
- Series A 1 (25%)
- Series D 1 (25%)
- Funding Round 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CartiHeal
|
CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. | Oct 29, 2013 | |
|
CartiHeal
|
CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. | Jul 09, 2012 | |
|
CartiHeal
|
CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. | Series D / Feb 01, 2012 | |
|
CartiHeal
|
CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. | $695K / Series A / Apr 11, 2009 |
Co-Investors
Accelmed
4 deals together
Elron Ventures
4 deals together
Johnson & Johnson Robotics and Digital Solutions
1 deal together
Peregrine Ventures
1 deal together
About Yale University
Yale University is a research institution that prioritizes its students and promotes education as a vital aspect of daily life.Yale University comprises three academic components: Yale College (the undergraduate program), the Graduate School of Arts and Sciences, and the professional schools. In addition, Yale encompasses a wide array of centersand programs, libraries, museums, and administrative support offices. Approximately 11,250 students attend Yale.
Yale University Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Zhong Shao
Professor Of Computer Science
|
|||
Arnaud Landragin
Doctoral Fellow
|
|||
Asher King-Abramson
Neuroscience Research
|
|||
Barry Nalebuff
Milton Steinbach Professor
|
|||
Barry Nalebuff
Milton Steinbach Professor
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michael Tal invest in?
Michael Tal invests primarily in Health Care, Manufacturing and Medical Device startups, most often at Series A and Series D stage. Most of the 4 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Michael Tal last invest?
The most recent investment recorded for Michael Tal closed in Oct 2013. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
